MedTrace Logo

Serum Vancomycin Levels in Patients Receiving Enteral Vancomycin

NCT00617227 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2010-02-10

No results posted yet for this study

Summary

The study is based on the hypothesis that decreased creatinine clearance may be associated with detectable vancomycin levels in patients on enteral (oral / vancomycin enemas) vancomyicn for CDAD.

The objective of the study is to see whether enteral vancomycin is absorbed through the inflamed GI mucosa in CDAD, and if it is absorbed, does it achieve measurable serum concentration.

Conditions

  • Clostridium Difficle Colitis
  • Clostridium Difficle Associated Disease

Sponsors & Collaborators

  • Maimonides Medical Center

    lead OTHER

Principal Investigators

  • Edward K Chapnick, MD · Maimonides Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-05-31
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00617227 on ClinicalTrials.gov